Stocks and Investing
Stocks and Investing
Fri, October 30, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lebovitz Downgraded (BPMC) to Hold on, Oct 30th, 2020
David Lebovitz of Morgan Stanley, Downgraded "Blueprint Medicines Corporation" (BPMC) to Hold on, Oct 30th, 2020.
David has made no other calls on BPMC in the last 4 months.
There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 0 agree with David's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with David
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $120 on, Thursday, October 29th, 2020
- Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $122 on, Friday, October 16th, 2020
- Andrew Berens of "Morgan Stanley" Maintained at Buy with Increased Target to $100 on, Tuesday, October 13th, 2020
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $110 on, Wednesday, July 15th, 2020
Contributing Sources